Cargando…

EMT is not required for lung metastasis but contributes to chemoresistance

The role of epithelial to mesenchymal transition (EMT) in metastasis is a longstanding source of controversy, largely due to an inability to monitor transient and reversible EMT phenotypes in vivo. We established an EMT lineage tracing system to monitor this process, using a mesenchymal-specific Cre...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Kari R., Durrans, Anna, Lee, Sharrell, Sheng, Jianting, Li, Fuhai, Wong, Stephen, Choi, Hyejin, El Rayes, Tina, Ryu, Seongho, Troeger, Juliane, Schwabe, Robert F., Vahdat, Linda T., Altorki, Nasser K., Mittal, Vivek, Gao, Dingcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662610/
https://www.ncbi.nlm.nih.gov/pubmed/26560033
http://dx.doi.org/10.1038/nature15748
_version_ 1782403183979528192
author Fischer, Kari R.
Durrans, Anna
Lee, Sharrell
Sheng, Jianting
Li, Fuhai
Wong, Stephen
Choi, Hyejin
El Rayes, Tina
Ryu, Seongho
Troeger, Juliane
Schwabe, Robert F.
Vahdat, Linda T.
Altorki, Nasser K.
Mittal, Vivek
Gao, Dingcheng
author_facet Fischer, Kari R.
Durrans, Anna
Lee, Sharrell
Sheng, Jianting
Li, Fuhai
Wong, Stephen
Choi, Hyejin
El Rayes, Tina
Ryu, Seongho
Troeger, Juliane
Schwabe, Robert F.
Vahdat, Linda T.
Altorki, Nasser K.
Mittal, Vivek
Gao, Dingcheng
author_sort Fischer, Kari R.
collection PubMed
description The role of epithelial to mesenchymal transition (EMT) in metastasis is a longstanding source of controversy, largely due to an inability to monitor transient and reversible EMT phenotypes in vivo. We established an EMT lineage tracing system to monitor this process, using a mesenchymal-specific Cre-mediated fluorescent marker switch system in spontaneous breast-to-lung metastasis models. We confirmed that within a predominantly epithelial primary tumor, a small portion of tumor cells undergo EMT. Strikingly, lung metastases mainly consisted of non-EMT tumor cells maintaining their epithelial phenotype. Inhibiting EMT by overexpressing miR-200 did not impact lung metastasis development. However, EMT cells significantly contribute to recurrent lung metastasis formation after chemotherapy. These cells survived cyclophosphamide treatment due to reduced proliferation, apoptotic tolerance, and elevated expression of chemoresistance-related genes. Overexpression of miR-200 abrogated this resistance. This study suggests the potential of an EMT-targeting strategy, in conjunction with conventional chemotherapies, for breast cancer treatment.
format Online
Article
Text
id pubmed-4662610
institution National Center for Biotechnology Information
language English
publishDate 2015
record_format MEDLINE/PubMed
spelling pubmed-46626102016-05-18 EMT is not required for lung metastasis but contributes to chemoresistance Fischer, Kari R. Durrans, Anna Lee, Sharrell Sheng, Jianting Li, Fuhai Wong, Stephen Choi, Hyejin El Rayes, Tina Ryu, Seongho Troeger, Juliane Schwabe, Robert F. Vahdat, Linda T. Altorki, Nasser K. Mittal, Vivek Gao, Dingcheng Nature Article The role of epithelial to mesenchymal transition (EMT) in metastasis is a longstanding source of controversy, largely due to an inability to monitor transient and reversible EMT phenotypes in vivo. We established an EMT lineage tracing system to monitor this process, using a mesenchymal-specific Cre-mediated fluorescent marker switch system in spontaneous breast-to-lung metastasis models. We confirmed that within a predominantly epithelial primary tumor, a small portion of tumor cells undergo EMT. Strikingly, lung metastases mainly consisted of non-EMT tumor cells maintaining their epithelial phenotype. Inhibiting EMT by overexpressing miR-200 did not impact lung metastasis development. However, EMT cells significantly contribute to recurrent lung metastasis formation after chemotherapy. These cells survived cyclophosphamide treatment due to reduced proliferation, apoptotic tolerance, and elevated expression of chemoresistance-related genes. Overexpression of miR-200 abrogated this resistance. This study suggests the potential of an EMT-targeting strategy, in conjunction with conventional chemotherapies, for breast cancer treatment. 2015-11-11 2015-11-26 /pmc/articles/PMC4662610/ /pubmed/26560033 http://dx.doi.org/10.1038/nature15748 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Fischer, Kari R.
Durrans, Anna
Lee, Sharrell
Sheng, Jianting
Li, Fuhai
Wong, Stephen
Choi, Hyejin
El Rayes, Tina
Ryu, Seongho
Troeger, Juliane
Schwabe, Robert F.
Vahdat, Linda T.
Altorki, Nasser K.
Mittal, Vivek
Gao, Dingcheng
EMT is not required for lung metastasis but contributes to chemoresistance
title EMT is not required for lung metastasis but contributes to chemoresistance
title_full EMT is not required for lung metastasis but contributes to chemoresistance
title_fullStr EMT is not required for lung metastasis but contributes to chemoresistance
title_full_unstemmed EMT is not required for lung metastasis but contributes to chemoresistance
title_short EMT is not required for lung metastasis but contributes to chemoresistance
title_sort emt is not required for lung metastasis but contributes to chemoresistance
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662610/
https://www.ncbi.nlm.nih.gov/pubmed/26560033
http://dx.doi.org/10.1038/nature15748
work_keys_str_mv AT fischerkarir emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT durransanna emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT leesharrell emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT shengjianting emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT lifuhai emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT wongstephen emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT choihyejin emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT elrayestina emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT ryuseongho emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT troegerjuliane emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT schwaberobertf emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT vahdatlindat emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT altorkinasserk emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT mittalvivek emtisnotrequiredforlungmetastasisbutcontributestochemoresistance
AT gaodingcheng emtisnotrequiredforlungmetastasisbutcontributestochemoresistance